130 related articles for article (PubMed ID: 12492078)
1. New partnership calls for clinical testing of two fusion inhibitors.
Slovick J
Posit Living; 1999 Aug; 8(7):15, 62. PubMed ID: 12492078
[No Abstract] [Full Text] [Related]
2. Fuzeon treatment forum, January 2004.
Burgess GE
Surviv News (Atlanta Ga); 2004; 15(1):10. PubMed ID: 15032144
[No Abstract] [Full Text] [Related]
3. Enfuvirtide (Fuzeon).
Proj Inf Perspect; 2003 Oct; (36):4-5. PubMed ID: 14696566
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials for enfuvirtide (Fuzeon, T-20).
Crabb C
AIDS; 2003 Nov; 17(17):N13-4. PubMed ID: 15065580
[No Abstract] [Full Text] [Related]
5. Enfuvirtide doubles chances for suppression.
AIDS Patient Care STDS; 2004 Sep; 18(9):550. PubMed ID: 15630779
[No Abstract] [Full Text] [Related]
6. [Fusion inhibitor enfuvirtidE. Continuous virologic and immunologic response].
Schäfer B
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():31. PubMed ID: 16385869
[No Abstract] [Full Text] [Related]
7. [Initial retroviral drug with new mechanism of action. Peptide T-20 enriches therapeutic arsenal].
MMW Fortschr Med; 2003 Apr; 145 Spec No 1():55-7. PubMed ID: 15011591
[No Abstract] [Full Text] [Related]
8. [Fusion inhibitors. One year therapy with T-20--initial evaluation].
Goebel FD
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():42-3. PubMed ID: 15373046
[No Abstract] [Full Text] [Related]
9. [Strategies for combating resistances in HIV therapy--an exemplifying case].
Stoehr A
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():70-1. PubMed ID: 15373056
[No Abstract] [Full Text] [Related]
10. T-1249 development suspended.
Huff B
GMHC Treat Issues; 2003 Dec; 17(12):6. PubMed ID: 15011643
[No Abstract] [Full Text] [Related]
11. Consensus recommendation from a group of German experts for the use of enfuvirtide in heavily pretreated HIV patients.
Salzberger B; Däumer M; Gute P; Jaeger H; Knechten H; van Lunzen J; Mauss S; Mayr C; Moll A; Plettenberg A; Rockstroh J; Staszewski S; Stellbrink HJ; Stoll M; Sturmer M
Eur J Med Res; 2007 Mar; 12(3):93-102. PubMed ID: 17507306
[TBL] [Abstract][Full Text] [Related]
12. Acute hypersensitivity reaction to enfuvurtide upon re-challenge.
Beilke MA
Scand J Infect Dis; 2004; 36(10):778. PubMed ID: 15513412
[No Abstract] [Full Text] [Related]
13. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
Pham PA
Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
[No Abstract] [Full Text] [Related]
14. A novel form of amyloid deposited at the site of enfuvirtide injection.
Naujokas A; Vidal CI; Mercer SE; Harp J; Kurtin PJ; Fox LP; Thompson MM
J Cutan Pathol; 2012 Feb; 39(2):220-1; quiz 219. PubMed ID: 22264247
[No Abstract] [Full Text] [Related]
15. FDA notifications. Enfuvirtide has new instructions.
AIDS Alert; 2007 Apr; 22(4):44-5. PubMed ID: 17595723
[No Abstract] [Full Text] [Related]
16. Enfurvirtide safety in human immunodeficiency virus-infected children.
Baylor MS; Johann-Liang R
Pediatr Infect Dis J; 2005 Apr; 24(4):389-90. PubMed ID: 15818309
[No Abstract] [Full Text] [Related]
17. The optimal use of enfuvirtide.
Gallant JE
Hopkins HIV Rep; 2003 May; 15(3):1-3. PubMed ID: 12809103
[No Abstract] [Full Text] [Related]
18. Fusion inhibition--a major but costly step forward in the treatment of HIV-1.
Tashima KT; Carpenter CC
N Engl J Med; 2003 May; 348(22):2249-50. PubMed ID: 12773653
[No Abstract] [Full Text] [Related]
19. Postmarketing use of enfuvirtide in veterans: provider compliance with criteria for use, overall efficacy, and tolerability.
Belperio PS; Mole LA; Halloran J; Boothroyd DB; Thomas IC; Backus LI
Ann Pharmacother; 2008 Nov; 42(11):1573-80. PubMed ID: 18940919
[TBL] [Abstract][Full Text] [Related]
20. [Enfuvirtide].
Gerstoft J
Ugeskr Laeger; 2004 Nov; 166(48):4355-7. PubMed ID: 15587625
[No Abstract] [Full Text] [Related]
[Next] [New Search]
